In a newly published paper, a well-regarded gene therapy pioneer has raised concerns about severe neurological and liver toxicity observed in animals treated with high doses of a gene therapy targeted against a rare and fatal neuromuscular disorder.

The scientist, Dr. James Wilson, had previously quit the board of Solid Biosciences (SLDB), over concerns that the virus the company uses in its gene therapy, being developed for patients with a form of muscular dystrophy, was too dangerous. In Tuesday’s paper, however, he and others laid out those concerns in more detail.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy